Canal-U

Mon compte
Canal-U/Médecine

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets: The value of omics and mendelian randomization studies (Daniel SWERDLOW)


Copier le code pour partager la vidéo :
<div style="position:relative;padding-bottom:56.25%;padding-top:10px;height:0;overflow:hidden;"><iframe src="https://www.canal-u.tv/video/canal_u_medecine/embed.1/cardiovascular_clinical_trialists_cvct_forum_paris_2012_workshop_5_identifying_new_targets_the_value_of_omics_and_mendelian_randomization_studies_daniel_swerdlow.11257?width=100%&amp;height=100%" style="position:absolute;top:0;left:0;width:100%;height: 100%;" width="550" height="306" frameborder="0" allowfullscreen scrolling="no"></iframe></div> Si vous souhaitez partager une séquence, indiquez le début de celle-ci , et copiez le code : h m s
Auteur(s) :
SWERDLOW Daniel

Producteur Canal-U :
Canal-U/Médecine
Contacter le contributeur
J’aime
Imprimer
partager facebook twitter Google +

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets: The value of omics and mendelian randomization studies (Daniel SWERDLOW)

MODIGLIANI Workshop 5 - Saturday December 1st, 2012
THE ATHEROSCLEROSIS TRIALISTS FORUM

Chairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBR
Webcast: Tabassome SIMON, Paris, FRA

Will new compounds be able to reduce the residual risk in high risk patients when treatment targets based on new ESC guidelines have been achieved (e.g. LDL-C < 70mg/dl)?
Despite widespread early intervention in acute coronary syndromes and complete revascularization of stenotic lesions complemented by aggressive polypharmacotherapy, still a high percentage of patients develop a secondary event.
This has been shown in various registries and recent data from the GRACE registry have suggested that we grossly underestimate long-term risk in these patients. Thus, despite all our current efforts there is room for improvement.
➢ A very active clinical research programme is delivering an important number of new potential therapeutic targets that
may be ready for trial testing.
 • Can OMICS technology help us out here in terms of new specific biomarkers taking advantage of the proteome, metabolome or the transcriptome?
 • What is the relevance of Mendelian Randomisation studies to investigate the potential causal role of biomarkers in the pathophysiology of disease and to identify and select new drug biotargets.
➢ One major question relates to the value of biomarker-guided and/or risk guided therapy and how to design appropriate trials to test these therapeutic strategies. Should therapy be targeted to patients with specific biomarkers profiles? e.g. low HDL, high inflammatory burden (elevated CRP), high Lp-PLA2 activity etc.?
➢ A fairly large number of lipid-associated new targets or targets reflecting other pathways of the complex atherosclerotic process are being evaluated in mechanistic imaging studies but also in large randomised controlled clinical trials looking for important cardiovascular endpoints. In all of these trials the standard of care is much better than seen in the real world situation. Thus, the question arises, whether these additional compounds will lead to a clinically significant reduction in cardiovascular events on top of optimal standard care.

Trials (Interventions)
➢ CETP inhibitors: dalcetrapib, anacetrapib, evacetrapib (DAL-Outcomes I, DAL-Outcomes II, DEFINE, REVEAL, evacetrapib, ApoA1 mimetics, ApoA1 Milano, AIM-HIGH, HPS-Thrive)
➢ Directly augmenting apo A-I: Intravenous apo A-I therapy, Recombinant apo A-I Milano/phospholipids (ETC-216), Purified native apo A-I/phospholipids (CSL-111/112)
➢ Oral upregulators of endogenous apo A-I production RVX-208: ASSURE, SUSTAIN
➢ Phospholipase inhibitors: VISTA-16, SOLID, STABILITY
➢ Anti-inflammatory therapy: CANTOS (IL-1β antibody), CIRT (MTX), Anakinra (IL1 RA), IL-6 RA (Taxilicumab)
➢ New LDL-lowering compounds: PCSK9 inhibitors, apoB antisense, ISIS

Session program:
Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials?
Speaker: Eric STROES, Amsterdam, NED
Discussant: Robert ROSENSON, New York, USA
Identifying new targets: The value of omics and mendelian randomization studies
Speaker: Juan Pablo CASAS, London, GBR
Identifying new targets: Monoclonal Antibody Inhibitor of PCSK9
Speakers: Wolfgang KOENIG, Ulm, GER - Robert SCOTT, Amgen, USA

  •  
  •  
    Date de réalisation : 1 Décembre 2012
    Durée du programme : 67 min
    Classification Dewey : Maladies de l'appareil cardio-vasculaire
  •  
    Catégorie : Conférences
    Niveau : Spécialités de médecine, Formation continue
    Disciplines : Santé publique environnement et société, Cardiologie
    Collections : CVCT 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012
    ficheLom : Voir la fiche LOM
  •  
    Auteur(s) : SWERDLOW Daniel
    producteur : Canal U/3S - CERIMES
    Réalisateur(s) : Canal U/3S - CERIMES
  •  
    Langue : Anglais
    Mots-clés : Maladies cardiovasculaires
 

commentaires


Ajouter un commentaire Lire les commentaires
*Les champs suivis d’un astérisque sont obligatoires.
Aucun commentaire sur cette vidéo pour le moment (les commentaires font l’objet d’une modération)
 

Dans la même collection

 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optimal dose(s) for phase III? (Michael GIBSON)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, different indications? (Freek VERHEUGT)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Efthymios DELIARGYRIS)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Faiez ZANNAD)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Krishna PRASAD)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Joerg KOGLIN)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Non randomized and/or non-blinded trials (Stuart POCOCK)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspective (Holger WOEHRLE)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optimal dose(s) for phase III? (Nancy GELLER)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Options of and alternatives to the “control group” in device trials (William T. ABRAHAM)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : Well Established Methods for Imaging Approaches, IVUS and IMT (Wolfgang KOENIG)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials? (Eric STROES)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Insights from DOSE and gaps in evidence with diuretic therapy (Alice MASCETTE)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Ultrafiltration for acute cardiorenal syndrome in heart failure (Gian Paolo ROSSI)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST (William T. ABRAHAM)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST (Michael FELKER)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials? (Robert ROSENSON)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : Treatment optimization (William T. ABRAHAM)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : What endpoint for securing approval and reimbursement (Andrew FARB - Ileana PIÑA)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : The value of repeat events in post discharge hospitalized HF trials (Stuart POCOCK)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Regulatory viewpoint (Yuki ANDO)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets: Monoclonal Antibody Inhibitor of PCSK9 (Wolfgang KOENIG)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Endpoint related issues (Alexandre MEBAZAA)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : PRONTO (Frank PEACOCK)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Execution issues (Mihai GHEORGHIADE)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : ASTRONAUT (Aldo MAGGIONI)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : RELAX-HF (Michael FELKER)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 :Regulatory viewpoint (Pieter DE GRAEF)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 :How to secure the optimal dose(s) for phase III? How to secure the optimal dose(s) for phase III?
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Approvability issues: Pathway to a more global device approval process (Ileana PIÑA)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and registry studies (Ileana PIÑA)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Comparative effectiveness studies (Kenneth STEIN)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Comparative effectiveness studies (Rita REDBERG)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspective (Rob KIEVAL)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and registry studies (Roxana MEHRAN)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : How much one could deviate from “randomized - controlled” trials? Questions
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Angeles ALONSO)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Christophe GAUDIN)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Kaori SHINAGAWA)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Lloyd HASKEL)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, different indications? (Maarten SIMOONS)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Dosing Issues, Questions
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Yasser KHDER)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : PET-CT imaging in clinical trials (James RUDD)
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries.
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries.
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkers
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and future developments
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trials
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : conclusion
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine.
 Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)
 Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.
 Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients
 Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients
 Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).
 Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)
 Cardiovascular Clinical Trialists (CVCT) Forum – Interpretation and approvability issues.
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Expected implications on heart failure epidemiology.
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Compound vs. class effect. Drug class recommendations in guidelinesCanadian, Australian CHF guideline and 2010 NICE guideline.
 Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Is it always safe to believe in class effect: Spironolactone vs. eplerenone differences and clinical relevance?
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries (debates).
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful? (debates)
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : Insulin in type 2 diabetes: bad guy or good guy?
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : What else than glucose control? Lipids, BP, Weight, Kidney
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy (debates).
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance (debates).
 Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : on top of or vs. Metformin? The issue of background therapy and comparator
FMSH
 
Facebook Twitter Google+
Mon Compte